Prothena (NASDAQ:PRTA) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts have also weighed in on PRTA. Deutsche Bank restated a “buy” rating on shares of Prothena in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $69.00 price objective on shares of Prothena in a report on Wednesday. Oppenheimer set a $70.00 price objective on shares of Prothena and gave the stock a “buy” rating in a report on Wednesday. ValuEngine lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a report on Wednesday, February 7th. Finally, Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 19th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. Prothena has a consensus rating of “Buy” and a consensus price target of $74.91.

How to Become a New Pot Stock Millionaire

Prothena (NASDAQ PRTA) opened at $38.21 on Friday. Prothena has a 12 month low of $27.19 and a 12 month high of $70.00. The company has a market cap of $1,301.42, a P/E ratio of -9.41 and a beta of 2.79.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.48) by $0.24. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.27 million. Prothena had a negative net margin of 556.84% and a negative return on equity of 33.37%. The business’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.41) EPS. analysts anticipate that Prothena will post -5.87 earnings per share for the current year.

A number of large investors have recently bought and sold shares of PRTA. Fieldpoint Private Securities LLC bought a new stake in Prothena during the 3rd quarter valued at $162,000. Teacher Retirement System of Texas bought a new stake in Prothena during the 3rd quarter valued at $206,000. First Trust Advisors LP bought a new stake in Prothena during the 3rd quarter valued at $212,000. HBK Investments L P bought a new stake in Prothena during the 4th quarter valued at $213,000. Finally, Jefferies Group LLC bought a new stake in Prothena during the 4th quarter valued at $292,000.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/prothena-prta-upgraded-by-bidaskclub-to-hold/1958598.html.

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.